Ybanez Larissa, Spiller Henry A, Badeti Jaahnavi, Casavant Marcel J, Rine Natalie, Michaels Nichole L, Zhu Motao, Smith Gary A
Center for Injury Research and Policy, The Abigail Wexner Research Institute of Nationwide Children's Hospital, Columbus, OH, USA.
University of the Incarnate Word School of Osteopathic Medicine, San Antonio, TX, USA.
Clin Toxicol (Phila). 2023 Apr;61(4):294-304. doi: 10.1080/15563650.2023.2185493. Epub 2023 Apr 3.
To investigate the patterns and trends of suspected suicides and suicide attempts involving antipsychotic or sedative-hypnotic medications reported to United States poison centers.
Data from the National Poison Data System for 2000 through 2021 were retrospectively analyzed.
There were 972,975 suspected suicides and suicide attempts with antipsychotics or sedative-hypnotics ranked as the primary substance reported to poison centers from 2000-2021, averaging 44,226 cases annually. Most (85.6%) cases occurred among individuals >19 years old, females accounted for 63.5% of cases, and 51.8% were single-substance exposures. The rate of reported exposures per 100,000 United States population increased significantly from 27.2 in 2000 to 49.1 in 2008 ( < 0.0001), then plateaued to 49.6 in 2016 ( = 0.1497), followed by a significant decrease to 38.7 in 2021 ( < 0.0001). Individuals 13-19 years old demonstrated the greatest increase in rate from 28.4 in 2000 to 79.6 in 2021 ( < 0.0001). Approximately half (48.8%) of primary substance exposures were benzodiazepines, followed by antipsychotic medications (36.7%) and other types of sedative/hypnotic/anti-anxiety or antipsychotic medications (14.6%). Most primary substance exposures were admitted to a critical care or non-critical care unit (43.3%) or directly to a psychiatric facility (27.9%), and 36.1% were associated with in a serious medical outcome, including 1,330 deaths. Individuals >49 years old were more likely to experience a serious medical outcome (relative risk = 1.25, 95% CI: 1.24-1.26), including death (relative risk = 3.06, 95% CI: 2.74-3.41), or be admitted to a critical care or non-critical care unit (relative risk = 1.24, 95% CI: 1.23-1.24) than younger individuals.
Suspected suicides and suicide attempts involving antipsychotic or sedative-hypnotic medications increased during the 22-year study period, especially among individuals 13-19 years old, and these cases often had severe clinical consequences. Based on the characteristics and trends identified in this study, increased prevention efforts are warranted to help prevent these suspected suicides and suicide attempts.
调查向美国毒物控制中心报告的涉及抗精神病药物或镇静催眠药物的疑似自杀和自杀未遂事件的模式及趋势。
对2000年至2021年国家毒物数据系统的数据进行回顾性分析。
2000年至2021年期间,有972,975起疑似自杀和自杀未遂事件,其中抗精神病药物或镇静催眠药物被列为向毒物控制中心报告的主要物质,每年平均有44,226例。大多数(85.6%)病例发生在19岁以上的人群中,女性占病例的63.5%,51.8%为单一物质暴露。每10万美国人口的报告暴露率从2000年的27.2显著增加到2008年的49.1(P<0.0001),然后在2016年稳定在49.6(P=0.1497),随后在2021年显著下降至38.7(P<0.0001)。13至19岁的个体的暴露率增加幅度最大,从2000年的28.4增加到2021年的79.6(P<0.0001)。大约一半(48.8%)的主要物质暴露涉及苯二氮䓬类药物,其次是抗精神病药物(36.7%)以及其他类型的镇静/催眠/抗焦虑或抗精神病药物(14.6%)。大多数主要物质暴露者被收治到重症监护或非重症监护病房(43.3%)或直接送往精神科机构(27.9%),36.1%与严重医疗后果相关,包括1330例死亡。49岁以上的个体比年轻个体更有可能经历严重医疗后果(相对风险=1.25,95%置信区间:1.24-1.26),包括死亡(相对风险=3.06,95%置信区间:2.74-3.41),或被收治到重症监护或非重症监护病房(相对风险=1.24,95%置信区间:1.23-1.24)。
在22年的研究期间,涉及抗精神病药物或镇静催眠药物的疑似自杀和自杀未遂事件有所增加,尤其是在13至19岁的个体中,并且这些病例往往具有严重的临床后果。基于本研究确定的特征和趋势,有必要加强预防措施以帮助预防这些疑似自杀和自杀未遂事件。